Poor Adherence to Placebo or Amiodarone Therapy Predicts Mortality: Results From the CAMIAT Study
Jane Irvine, DPhil, CPsych,
Brian Baker, MBChB, FRCPC,
Janice Smith, MSc,
Stacey Jandciu, BSc,
Miney Paquette, MA,
John Cairns, MD, FRCPC,
Stuart Connolly, MD, FRCPC,
Robin Roberts, MT,
Michael Gent, DSc and
Paul Dorian, MD, FRCPC
From the The Toronto Hospital (J.I., B.B., J.S., S.J.), Departments of Psychiatry (J.I., B.B.) and Medicine (P.D.), University of Toronto, and St. Michaels Hospital (M.P., P.D.), Toronto, Ontario; Dean, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (J.C.); and Departments of Medicine (S.C.) and Clinical Epidemiology and Biostatistics (R.R., M.G.), McMaster University, Hamilton, Ontario, Canada.

View larger version (14K):
[in a new window]
|
Fig. 1. Risk of SCD in placebo-treated patients. The x axis is survival time (in days), and the y axis is the cumulative proportion of patients free of SCD.
|
|

View larger version (14K):
[in a new window]
|
Fig. 2. Risk of SCD in amiodarone-treated patients. The x axis is survival time (in days), and the y axis is the cumulative proportion of patients free SCD.
|
|
Copyright © 1999 by the American Psychosomatic Society